Vaxart (VXRT) Q2 2026 Earnings Report

The call presents a balanced mix of encouraging clinical and operational developments alongside material financial and timing risks. Key positives include a clean 12‑month safety signal in the sentinel cohort, BARDA’s $29 million contract modification enabling deeper analyses, a fully enrolled ~5,000‑participant main cohort with topline expected H1 2027, governance improvements, and a defined cash runway with flexible financing options. Offsetting these are a ~31.5% year‑over‑year revenue decline, a limited cash runway into Q2 2027 that creates timing pressure for funding or partner opt‑ins, reliance on BARDA for data release timing, uncertainty around the norovirus partnership and development timelines, and that the sentinel cohort was not powered to demonstrate efficacy (symptomatic case counts were similar between arms). On balance, positives (safety readout, BARDA support, large main cohort enrollment, governance actions) are meaningful but are matched by significant near‑term financing and commercialization uncertainties; the overall tone is constructive but cautious.

Management reiterated that top-line efficacy and safety from the Phase IIb main cohort of ~5,000 participants is expected in H1 2027, following positive 12‑month safety data from the 400‑participant sentinel cohort (201 oral pill, 199 mRNA) that showed 0 vaccine‑related serious adverse events, symptomatic COVID in 33 pill vs 30 mRNA recipients and 12 asymptomatic cases in each arm; reported side‑effect rates for the pill were ~20.9% fatigue, 18.9% headache and ~10% loss of appetite versus >60% injection‑site pain, 40.2% tenderness, 35.2% fatigue, 33.2% muscle pain and 28.6% headache for the mRNA comparator. Financially, Vaxart ended Q2 2026 with $64.0M cash and a cash runway into Q2 2027, Q2 revenue was $27.2M (vs $39.7M YoY), R&D expense $33.7M (vs $49.7M), G&A $6.6M, and net loss $13.5M or $0.06/share (vs $15.0M or $0.07/share prior year); management also cited a $29M BARDA contract modification to fund expanded mucosal, genomic and cellular analyses across the 5,000+ cohort, an available $25M Lincoln Park equity facility, and that BARDA controls timing/content of data releases.